M&A Deal Summary |
|
|---|---|
| Date | 2021-03-01 |
| Target | TruBiotics |
| Sector | Life Science |
| Buyer(s) | PanTheryx |
| Sellers(s) | Bayer |
| Deal Type | Divestiture |
SEARCH BY
PanTheryx is a global medical nutrition company and is dedicated to improving global health and quality of life through innovative life science. Utilizing its broad-based proprietary technology platform, PanTheryx is focused on the development and commercialization of medical nutrition products that target the gastrointestinal microbiome. PanTheryx was established in 2007 and is based in Boulder, Colorado.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Florida M&A | 1 of 1 |
| Country: United States M&A | 4 of 4 |
| Year: 2021 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-10-14 |
Goodgut
Palo Alto, California, United States Goodgut is a manufacturer of prebiotic supplements to help people lead better, healthier lives. Goodgut proprietary, active ingredient Preliva has been shown to help manage digestive distress and sustain digestive health. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1863 |
| Sector | Life Science |
| Employees | 89,556 |
| Revenue | 46.6B EUR (2024) |
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer was founded in 1863 and is based in Leverkusen, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 16 of 23 |
| Sector: Life Science M&A | 3 of 6 |
| Type: Divestiture M&A Deals | 12 of 19 |
| State: Florida M&A | 1 of 1 |
| Country: United States M&A | 5 of 7 |
| Year: 2021 M&A | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-10-26 |
AskBio
Research Triangle Park, North Carolina, United States Asklepios BioPharmaceutical, Inc. is a clinical-stage gene therapy platform company dedicated to improving the lives of children and adults with rare genetic disorders. AskBio’s gene therapy platform includes an industry-leading proprietary cell line manufacturing process known as Pro10TM and an extensive AAV capsid library. AskBio maintains a portfolio of clinical programs across a range of indications including Pompe, Limb-Girdle Muscular Dystrophy, Cystic Fibrosis, Myotonic Muscular Dystrophy, Hemophilia (Chatham Therapeutic/Takeda) and Duchenne Muscular Dystrophy (Bamboo Therapeutics/Pfizer). AskBio was established in 2001 and is based in Research Triangle Park, North Carolina. |
Buy | $2.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-07 |
Bayer Wuppertal
Wuppertal, China Bayer Wuppertal produces around 20 active ingredients for the world market in the plant and the processes are sustainably developed. Bayer Wuppertal site consists of four parts of the plant: the plant on the Wupper, the research and development center, and the works sewage treatment plant as well as a branch in Cologne. |
Sell | - |
